NeuroSense Welcomes Alzheimer's Expert Prof. Steven Arnold
Alzheimer's Clinical and Biomarker Outcomes Expected Soon
CAMBRIDGE, Mass. — NeuroSense Therapeutics Ltd. (NASDAQ: NRSN), a biotechnology company focused on developing treatments for severe neurodegenerative disorders, has announced a significant enhancement to its scientific leadership. Prof. Steven E. Arnold, an esteemed authority in Alzheimer's disease, has joined the Company's Scientific Advisory Board. Renowned for his extensive research experience, Prof. Arnold aims to fortify NeuroSense’s strategic initiatives as it advances its promising therapies, including PrimeC for ALS and its expanding Alzheimer's program.
Alon Ben-Noon, Co-Founder and Chief Executive Officer of NeuroSense, expressed enthusiasm about Prof. Arnold's addition, stating, "Prof. Arnold's extensive background in biomarker-focused clinical development and translational neuroscience will be invaluable as we push forward with our Alzheimer's and ALS initiatives. His insights are expected to play a crucial role in our research efforts."
Prof. Arnold himself expressed eagerness regarding his role, highlighting the importance of PrimeC’s multi-faceted approach to targeting critical biological pathways related to Alzheimer's disease. He stated, "I look forward to the upcoming clinical and biomarker data and to meaningfully contributing to the progression of our programs. Both patients and families dealing with these conditions deserve advancements in treatment options."
Recently, NeuroSense completed its proof-of-concept study related to Alzheimer's disease, known as RoAD. The preliminary findings have shown a promising safety profile, with clinical and biomarker outcomes anticipated in the near future.
Understanding Alzheimer's Disease
Alzheimer's disease (AD) stands as a formidable challenge, being the primary cause of dementia worldwide. Currently, it affects over 30 million individuals globally. The disorder predominantly manifests through memory distortion, cognitive decline, and notable behavior changes, all while remaining untreatable with existing therapies, which merely alleviate symptoms. This substantial gap highlights the urgent need for innovative disease-modifying treatments capable of genuinely slowing or halting its progression. NeuroSense recognizes the intricacy of AD, thereby advocating for comprehensive strategies that simultaneously address various mechanisms, like its flagship therapy, PrimeC.
About PrimeC
PrimeC emerges as NeuroSense's leading drug candidate, characterized by its unique extended-release formulation that comprises a carefully crafted combination of two FDA-approved medications: ciprofloxacin and celecoxib. This innovative drug is designed to effectively target significant factors contributing to neuron degeneration, inflammation, iron buildup, and compromised ribonucleic acid (RNA) regulation, potentially curbing the progression of both ALS and AD. Through its multi-target mechanism, PrimeC aims to make impactful strides in the holistic management of these neurodegenerative diseases.
About NeuroSense Therapeutics
NeuroSense Therapeutics, Ltd. stands at the forefront of clinical-stage biotechnology, with a mission to discover and implement effective therapies for devastating neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS), Alzheimer's disease, and Parkinson's disease. This commitment stems from the recognition that these conditions represent a crucial unmet medical need in today's healthcare landscape, with few effective treatment modalities accessible to patients. Emphasizing scientific rigor and a solid foundation in biomarker research, NeuroSense focuses on developing integrative therapies that target multiple disease pathways.
For those interested in learning more, additional information is available on our website, and we encourage you to connect with us through our relevant social media platforms for the latest updates. Our commitment to investors includes regular communication of important insights via our online resources.
Frequently Asked Questions
What role does Prof. Steven Arnold play at NeuroSense?
Prof. Steven Arnold has joined the Scientific Advisory Board, bringing his expertise in Alzheimer’s research to advance NeuroSense’s initiatives.
What is PrimeC?
PrimeC is NeuroSense’s leading drug candidate, designed to target mechanisms involved in ALS and Alzheimer's through a novel formulation of two FDA-approved drugs.
When can we expect clinical results from NeuroSense?
The clinical and biomarker outcomes from NeuroSense’s Alzheimer’s study are anticipated in the first quarter of 2026.
What is the primary goal of NeuroSense Therapeutics?
NeuroSense aims to develop effective treatments for patients suffering from debilitating neurodegenerative diseases, addressing significant unmet medical needs.
How does NeuroSense plan to tackle Alzheimer’s disease?
NeuroSense is focused on developing therapies like PrimeC that target multiple mechanisms of Alzheimer's to achieve meaningful therapeutic progress for patients.
